Caricamento...
Capsid Modifications for Targeting and Improving the Efficacy of AAV Vectors
In the past decade, recombinant vectors based on a non-pathogenic parvovirus, the adeno-associated virus (AAV), have taken center stage as a gene delivery vehicle for the potential gene therapy for a number of human diseases. To date, the safety of AAV vectors in 176 phase I, II, and III clinical tr...
Salvato in:
| Pubblicato in: | Mol Ther Methods Clin Dev |
|---|---|
| Autori principali: | , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
American Society of Gene & Cell Therapy
2019
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6378346/ https://ncbi.nlm.nih.gov/pubmed/30815511 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.omtm.2019.01.008 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|